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We traced the coronavirus classification and evolution, analyzed the 
Covid-19 composition and its distinguishing characteristics when compared 
to SARS-CoV and MERS-CoV. Despite their close kinship, SARS-CoV 
and Covid-19 display significant structural differences, including 380 
amino acid substitutions, and variable homology between certain open 
reading frames that are bound to diversify the pathogenesis and virulence 
of the two viral compounds. A single amino acid substitution such as 
replacing Aspartate (D) with Glycine (G) composes the D614G mutation 
that is around 20% more infectious than its predecessor 614D. The B117 
variant, that exhibits a 70% transmissibility rate, harbours 23 mutants, 
each reflecting one amino acid exchange. We examined several globally 
spreading mutations, 501.V2, B1351, P1, and others, with respect to the 
specific amino acid conversions involved. Unlike previous versions of 
coronavirus, where random mutations eventually precipitate extinction, the 
multiplicity of over 300,000 mutations appears to have rendered Covid-19 
more contagious, facilitating its ability to evade detection, thus challenging 
the effectiveness of a large variety of emerging vaccines. Vaccination 
enhances immune memory and intelligence to combat or obstruct viral 
entry by generating antibodies that will prohibit the cellular binding and 
fusion with the Spike protein, restricting the virus from releasing its 
contents into the cell. Developing antibodies during the innate response, 
appears to be the most compelling solution in light of the hypothesis 
that Covid-19 inhibits the production of Interferon type I, compromising 
adaptive efficiency to recognize the virus, possibly provoking a cytokine 
storm that injures vital organs. With respect to that perspective, the potential 
safety and effectiveness of different vaccines are evaluated and compared, 
including the Spike protein mRNA version, the Adenovirus DNA, Spike 
protein subunits, the deactivated virus genres, or, finally, the live attenuated 
coronavirus that appears to demonstrate the greatest effectiveness, yet, 














1. Coronavirus Evolution 
The corona virus is a positive RNA virus enveloped 
by a membrane that was first identified in Wuhan in 2019 
(SARS-CoV2 or Covid-19). It is classified under the beta 
coronaviruses category along with SARS-CoV (Severe 
Acute Respiratory Syndrome) and MERS CoV (Middle 
East Respiratory Syndrome). There are other beta type of 
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human coronaviruses that cause enteric and upper respi-
ratory tract infections, experienced during the common 
cold, such as the HCoV-OC43 and HCoV-HKU1. On the 
other hand, HCov-229D and HCoV-NL63 come under the 
alpha classification. Feline (FCoVs) and canine corona vi-
ruses (CCoVs) are also sorted under the alpha group. The 
remaining coronaviruses fall under the genera of gamma 
and delta categories that primarily affect poultry, wildlife 
and other birds, although rather sparce information is 
available regarding the delta division [1-2]. Very different 
types of viruses such as the Bafinivirus infects fish, while 
the Aterivirus is isolated in specific species including 
mice, monkeys, horses and pigs [3]. 
The highly contagious Covid-19 pandemic, resulting 
in 172,666,073 cases and 3,711,545 deaths globally by 
May 2021, has been one of the primary focuses of sci-
entific research and review. Unlike the MERS-CoV that 
uses adenosine deaminase complexing protein 2, also 
known as Dipeptidyl peptidase-4 (CD26), as its primary 
receptor, both SARS-CoV and Covid-19 (SARS-CoV2) 
target and fuse with the angiotensin-converting enzyme 2 
(ACE2) that serves as the viral portal into the cell. During 
their multiplication process, all viruses evolve to outlive 
the immune counterattack. Interestingly, these mutations 
appear to enhance the effectiveness and transmissibility 
of Covid-19, in contrast to other types of coronaviruses 
which are adversely affected by repeated mutations, even-
tually becoming extinct.
2. Coronavirus Composition
The genome of corona viruses is composed by se-
quences of around 26,000-32,000 variations of the ribonu-
cleic acid (RNA) nitrogenous bases: adenosine, cytosine, 
guanine, and uracil. It harbours 6-11 open reading frames 
(ORFs), 67% of which encode 16 non-structural proteins 
(nsps) that direct virus assembly, transcription and repli-
cation in connection with the host, and the rest encode the 
accessory and structural proteins. Structural proteins in-
clude the main surface trimeric Spike glycoprotein (S) that 
binds and fuses with the ACE2 receptor, a key to lock pro-
cess that releases the viral RNA into the cells; the smaller 
surface envelope (E) protein, the membrane (M), and the 
nucleocapsid (N) viral protein that defensively surrounds 
the genome. The N protein offers protection and signature 
sequences, equipping the virus with adaptation skills that 
enable it to survive the adversities of the host’s environ-
ment. The immune defence assembled against the antigen 
is composed by: A/ antibodies (innate immune system) 
that prophylactically cover the ACE2 receptor to obstruct 
the Spike’s contact and fusion with the human cells; and 
B/ the adaptive immune response comprised by a num-
ber of cells including cytotoxic T-killer cells or CD8+ 
that clasp onto the infected cells’ antigens, and obliterate 
them by releasing perforin and granzyme that is absorbed 
through the cellular pores [4-5].
2.1 The Kinship between SARS-CoV and Covid-19
The SARS-CoV and Covid-19 genomes are similar, 
however, there are important differences that may hinder 
upon the Covid-19 rate of infectiousness and virulence. 
Covid-19 is missing the 8a accessory protein that is pres-
ent in SARS-CoV. The Covid-19 8b accessory protein has 
37 more amino acids than SARS-CoV; and the SARS-
CoV 3b has 132 more amino acids than Covid-19. Over-
all, SARS-CoV and Covid-19 have significant structural 
differences that amount to 380 amino acid substitutions; 
for example, the non-structural nsp3 protein has 102 vari-
ations in its amino acid sequence, the nsp2 has 61 amino 
acid conversions, and the Covid-19 Spike protein has 27 
different amino acids’ exchanges than SARS-CoV [6-7]. 
Therefore, despite their kinship, the two viral configura-
tions, SARS-CoV and Covid-19 are packed with different 
messages that are bound to have important implications 
pertaining to their pathogenetic effects. 
The S gene that encodes the Spike protein in Covid-19 
is approximately 24% different from the S gene in SARS-
CoV, and 65% different from the S gene in MERS-
CoV. The N gene that encodes the nucleocapsid protein 
has around 90% homology between SARS-CoV and 
Covid-19, but only 48% between MERS-CoV and 
Covid-19. The E and M proteins’ genes of Covid-19 have 
a 94% and 90% similarity with the SARS-CoV E and 
M genes respectively. Moreover, a comparison between 
Covid-19 and SARS-CoV has unveiled significant differ-
ences between the open reading frames ORF3a, ORF6, 
and ORF8, with homology rates of only 72%, 68%, and 
40% respectively. The ORF7a appears to have the highest 
similarity rate, approaching 85% [8-10].
The trimeric spike (S) protein undergoes a structural 
transformation while binding with the ACE2 receptor. As 
a result, the S1 subunit sheds, allowing the S2 subunit to 
fuse with the receptor. This process is common in both 
SARS-CoV and Covid-19. The structural transformation 
of the S1 subunit consists of two conformation states, the 
up that exposes and makes the viral receptor available and 
the down that closes off the receptor. However, in SARS-
CoV the down conformation of the receptor binding 
domain clicks into the N-terminal domain of the trimeric 
Spike (S) protein, while in the Covid-19, the down recep-
tor fits into the central cavity of the trimer. [11-12]. This may 
be of significance under the assumption that the N-terminal 
domain remains available, in light of recent findings that 
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certain human antibodies bind with the N-terminal domain 
(NTD). NTD targeting human antibodies can be added to 
those binding with the receptor binding domain (RBD) for 
greater therapeutic efficiency [13-14].
2.2 Covid-19 Neutralizing Antibodies
Covid-19 neutralizing antibodies are Y shaped proteins 
that can recognize the S1 RBD and fit into the viral an-
tigens like a key to a lock. This prohibits the virus from 
binding with the ACE2 cellular receptor, thus preventing 
viral entry. Other antibodies can neutralize the heptad re-
peat 2 (HR2) domain to impede S2 fusion with the ACE2 
receptor, so even if the Spike protein can bind with the 
ACE2 receptor, the second step of antigen/receptor fusion 
is compromised, disallowing Covid-19 entry into the cells, 
without which the virus can neither replicate, nor spread 
inside the body [15].
A recent study experimented on a powerful monoclonal 
antibody, LY-CoV555, that binds with the Covid-19 spike 
protein obstructing it from fusing with the cells’ ACE2 
receptors. The results of 309 patients who received the LY-
CoV555 antibody treatment were compared to 148 patients 
who received placebo. Eighty percent of all 452 partici-
pating patients had mild Covid-19 symptomatology. By 
the 11th day of clinical observation both experimental and 
placebo group had a significantly reduced viral load, with 
the treated patients exhibiting a modest advantage. The 
experimental group patients who received a 2800mg anti-
body dose had a -0.53 difference from the placebo group 
(p=0.02 / p<0.05), which is a statistically significant result; 
notably, however, neither a lower dose of 700mgs (p=0.38) 
nor a higher dose of 7000mgs (p=0.7) were statistically 
significant. Importantly, when the rate of hospitalizations 
was examined on the 29th day, the percentage of the viral 
load in the experimental group that was treated with LY-
CoV555, was 1.6%, contrasted with the significantly high-
er viral load of the placebo / control group that was 6.3%. 
Further analysis focusing on high risk aged (>65) and 
obese (BMI>35) individuals denoted a diminished hos-
pitalization rate of 4.2% for those receiving LY-CoV555, 
when compared to 14.6% of non-treated patients [16]. 
2.3 Immune Memory
Immune memory that develops from milder forms of 
coronaviruses such as the HCoV variants (229E, NL63, 
OC43, HKU1) which cause the common cold, may be a 
significant factor contributing in the activation of immune 
defences to obstruct the virus, and/or reduce the viral load 
that diminishes contagion [17-18]. Immune memory pertains 
to antibodies that are secreted by B cells, the adaptive 
immune system killer-T cells (CD8+) that obliterate in-
fected cells, and helper T cells (CD4+) that are in charge 
of activating cytokines [21]. Unfortunately, recent studies 
have shown that individuals infected with milder forms 
of coronavirus related to the common cold do not develop 
neutralizing antibodies that can be useful in Covid-19 [19]. 
However, the cytotoxic CD8+ T cells have indicated a lon-
ger lasting SARS-CoV viral recognition, as illustrated by 
research evidencing that CD8+ T cells were reminiscent 
in 60.9% of SARS-CoV recovered patients for at least six 
years, whereas these patients’ B cells specific memory, 
that is crucial in generating antibodies, appeared to be 
negligible or absent [20]. Obviously, the longer lasting the 
immune memory, the superior the immune intelligence. 
This is the purpose of vaccination: to enhance inherent 
immune memory by presenting the Spike protein that in-
forms the immune system of the malevolence of the ene-
my, thus prohibiting future binding and fusion between the 
Spike trimer and the ACE2 receptors. This type of innate 
immune “education,” designed to obstruct viral entry alto-
gether, is particularly useful in the elderly, whose adaptive 
immune response is compromised due to aging, and who 
will be inherently more vulnerable in combating the anti-
gen via the adaptive immune defences, once Covid-19 has 
invaded human cells and has started multiplying [21]. 
2.4 Robust CD4+ T and CD8+ T cells Memory
A recent study has identified CD4+ T cells which ap-
peared to be reactive to Covid-19 Spike (S) glycoprotein of 
83% of Covid-19 patients, targeting epitomes in both the N 
and C terminals of S, as well as in 34% of healthy controls, 
despite the fact that the target was limited to the C termi-
nal. These investigators entertained the possibility that the 
CD4+ T cells found in healthy controls that were reactive to 
Covid-19 S protein, may be the result of previous exposure 
to the common cold variant virus under the HCoV umbrel-
la [22]. Another recent study revealed that Covid-19 patients 
have 70% of reactive CD8+ cytotoxic cells and 100% of 
CD4+ helper cells, which appeared to recognize the Spike, 
Membrane and Nucleocaspid proteins, as well as certain 
non-structural proteins (nsp3, nsp4) and open reading 
frames (ORF3a and ORF8). Additionally, they identified 
50% of CD4+ T helper cells and 20% of CD8+ T cytotoxic 
cells reacting to the Spike, Membrane, and non-struc-
tural proteins in individuals that had tested negative to 
Covid-19, again suggesting that these cytotoxic and helper 
T cells’ reactivity was obtained from previous exposures to 
milder coronavirus forms such as HCoV-OC43 and HCoV 
NL63 which, as previously noted, are responsible for the 
“common cold.” The CD4+ and CD8+ cells’ reactivity to 
open reading frames (ORFs) is significant, considering that 
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ORFs encode both non-structural and structural proteins as 
well as assembly ones [23].
The immune memory of CD4+ and CD8+ T cells is an 
encouraging finding. However, allowing Covid-19 to enter 
the system which will occur in the absence of antibod-
ies, may be already too late, especially in the elderly, or 
immunosuppressed individuals. The optimum method of 
fighting Covid-19 is focusing on antibodies that can block 
viral invasion in the first place. This is important for two 
reasons: a/ Preventing viral entry into the cells is the safest 
option. Once Covid19 enters the cells, the CD8+ cells must 
exterminate the infected cells, a necessary intervention, but 
a casualty nevertheless, that can often injure the host. b/ 
There is evidence that coronavirus inhibits the interferon 
type I production and therefore, it suppresses the ability of 
the adaptive immune system to recognize the virus, possi-
bly leading to the destruction of healthy cells. This is illus-
trated by the cytokine storm that indiscriminately attacks 
and rampages the host’s vital organs [24-26]. What seems 
to happen during the cytokine storm is that the adaptive 
immune system is informed about the lethal danger, but 
has difficulty identifying the enemy that is evasive and 
imperceptible due to insufficient availability of Interferon 
I. As a result, immune counterattack is persistently fierce 
yet, undifferentiating, with deleterious consequences for 
the human body. The inhibition of the interferon type I 
production that compromises adaptive efficiency can be 
particularly detrimental to aged individuals with compro-
mised immunity, who are faced by viral influx, and rely on 
the adaptive immune system for protection. This is why 
neutralizing antibody treatments have become so promis-
ing in the treatment of older Covid-19 patients. 
3. Vaccines
Covid-19 messenger ribonucleic acid (mRNA) based 
vaccines, like the two-dose Pfizer/BioNTech and Moderna 
vaccines, that have now received emergency use authori-
zation from the FDA, are developed by first sequencing 
the gene of the S protein, followed by a transcription of 
its mRNA, and finally encapsulating the nucleotide-modi-
fied messenger in a lipid nanoparticle that is subsequently 
delivered within a sterile saline solution, acting as a di-
lutant, into the muscles of the host’s upper arm. mRNA 
is a single stranded molecular sequence that can be read 
by the host’s ribosomes. The intention is to introduce the 
immune system to the configuration of the Spike protein, 
provoking it to produce the specific antibodies that can 
defensively wrap around the Spike protein to prohibit vi-
ral binding, fusion and entry into the human cells [27]. The 
Moderna vaccine encodes the Covid-19 S1 subunit of the 
spike trimer that binds with the ACE2 receptors, as well 
as the S2 one that fuses with the ACE2 receptors, releas-
ing the viral RNA into the cells. For additional safety, the 
S2 subunit is stabilized by substituting two amino acids at 
two consecutive positions, 986 and 987, by prolines which 
are secondary amines that do not contain the amino-group 
-NH, often used in the biosynthesis of proteins.
The vaccine’s effect on children under twelve years of 
age, pregnant women and individuals with specific pre-ex-
isting conditions is currently unclear, since the above 
mentioned populations were excluded from the clinical 
studies. Additional unknowns involve the vaccine’s inter-
action with a wide range of medications; the durability of 
immune protection against viral infection; and the vaccine 
efficiency against new viral mutations [28]. 
Two other vaccines are produced by inserting the Ad-
enovirus’ DNA which also contains an S protein, after 
deleting part of its genetic sequence, hence rendering it 
unable to replicate. The AstraZeneca vaccine uses the 
Adenovirus found in chimpanzees, while the Johnson and 
Johnson vaccine uses an Adenovirus derived from hu-
mans. Other vaccine research companies like the Novavax 
and Sanofi-GlaxoSmithKline produce the spike protein 
vaccines in insect cells out of recombinant baculovirus [29]. 
Protein subunit vaccines utilise an isolated protein, in this 
case the Spike protein, which is purified from any viral 
infectious components to establish safety, and provide im-
munocompromised individuals with the best alternative. 
The problem arises when the isolated protein becomes 
denatured, losing its quaternary, tertiary or secondary 
structure as well as its functionality, thus failing to stim-
ulate the immune production of the necessary antibodies 
that can ultimately protect the system against Covid-19. 
Therefore, its high safety may be undermined by its po-
tentially compromised efficiency [30].
An alternative method is vaccination with a Covid-19 
virus that has been deactivated and therefore, it is unable 
to reproduce, like for example, CoronaVac, a deactivated 
vaccine, produced by the Beijing based biopharmaceutical 
company, Sinovac. Deactivated vaccines’ research started 
by obtaining different Covid-19 strains from hospitalized 
patients around the world including China, Italy, Switzer-
land, United Kingdom and Spain, and has chemically inac-
tivated the hazardous viral features, leaving a purified, dis-
armed Covid-19 version that can no longer assail the body. 
Introducing the sight of the inactivated virus prepares the 
body to anticipate future viral invasion and encompass im-
mune defences by eliciting potent antibodies, which have 
so far demonstrated an ability to neutralize at least 10 viral 
mutations in mice, rats and nonhuman primates. The PiCo-
Vacc was formed by deactivating the CN2 strain and test-
ing it against CN3, CN5 and OS6, as well as the CN1 and 
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OS1, which are closely related to the Covid-19 mutations 
observed in Wuhan that evinced severe clinical symptoms. 
These investigators report that the purified inactivated virus 
exhibited genetic stability, despite multiple passages. The 
comparison of the different purification stages unveiled 
minor amino acid substitutions in the Envelope protein 
- residue 32, which replaced Alanine (A) with Aspartate 
(D). It also presented an interchange between Threonine 
(T) with Isoleucine (I) in the non-structural protein nsp10 - 
residue 49. Genetic stability persisting despite inactivation, 
signifies that the immune system should be able to recog-
nize and create antibodies to potentially protect the cells 
from future mutations. Immune recognition should occur 
despite future alternations of the Spike protein, designed 
to disguise it, so that it eludes antibodies, inconspicuously 
succeeding in infecting the cells [31-32].
3.1 Vaccines’ Comparison
Theoretically, the protein subunit, as well as the RNA / 
DNA vaccines appear to demonstrate both safety and effec-
tiveness. The Spike mRNA can only express the S protein, 
which is only one out of around 29 primary proteins that 
compose Covid-19, thus making it impossible for the virus 
to replicate. The DNA vaccine is not even based on the 
Covid-19 virus and its genetic sequence is altered to disable 
reproduction within the cell. As a result of the vaccination, 
the B cells can produce antibodies for the particular S pro-
tein configuration presented, thus obstructing the Covid-19 
spike protein from targeting and fusing with human cells. 
However, any formation of immune memory resulting from 
this process can be rendered ineffective by a viral mutation 
that substantially disguises the S protein to be unrecogniz-
able by the immune system. On the other hand, the genetic 
stability of inactivated vaccines could perhaps offer protec-
tion against several mutated strains; however, it is unclear 
whether accurately examining and mapping certain current 
strains can extend to future emerging ones. Additionally, 
it is unclear how many vaccine dosages will be warranted 
with the inactivated virus vaccines; and what will be their 
final level of effectiveness and durability [33].
Live attenuated virus vaccines are based on whole 
viruses that have been modified and hence weakened. A 
single dosage can stimulate immune responses against a 
wide variety of viral proteins, without infecting the body 
with the disease. However, a mutation in live attenuated 
viral compounds could potentially reinstate their harmful 
potency; or they may have deleterious consequences in in-
dividuals with compromised immunity. Moreover, in light 
that Covid-19 is excreted in the feces, there is a risk of 
transmitting the attenuated viral compound to healthy in-
dividuals, and the potential of viral fusion with alternative 
wild-type Cov versions [34]. 
4. Covid-19 Mutations
Covid-19 represents a mutation with a higher contagion 
rate when juxtaposed against SARS-CoV. Covid-19 Spike 
(S) protein binds with the ACE2 receptor in a manner that 
is 10 times more secure and steadfast than the juncture 
formed between the SARS-CoV spike protein with the 
ACE2 receptor. This finding pertains to both the Covid-19 
increased rate of viral infection and transmissibility, 
explaining the speed with which Covid-19 has spread 
globally [35]. Since it first appeared in Wuhan, Covid-19 
has mutated from 614D to 614G, basically exchanging 
the amino acid Aspartate (D) with the amino acid Glycine 
(G) in the genome’s 614 position [36]. Korber et al. (2020) 
looked at single amino acid changes in 28,576 sequences 
of the trimeric spike (S) protein that included both the 
subdomain Spike 1 (S1), which mediates the binding with 
the ACE2 receptor, and the Spike 2 (S2) subdomain that 
accomplishes the membrane fusion, ultimately resulting 
in the release of viral contents into the cell. These investi-
gators found that the Spike variant D614G that exchanges 
Aspartate with Glycine had a significantly higher rate of 
transmissibility globally, when compared to its prede-
cessor 614D. Several countries were affected including 
Eurore, the USA, Canada and Australia. This new mu-
tation D614G varied only 0.3% from the original 614D 
Covid-19 sequence that was identified in Wuhan. Inter-
estingly, this mutation that was solely based on a single 
substitution of the amino acid Aspartate (D) by the amino 
acid Glycine (G) in Spike’s 614th amino acid position, re-
sulted in an increase of at least 20% in the viral infectious-
ness rate [37]. While 614D only involves one conformation, 
D614G exhibits two to three Spike protein conformations, 
thus increasing the probability of contagion [38].
Covid-19 genome has undergone several mutations, 
usually based on one or two amino acid substitutions that 
reflect the virus’ adaptation to each host’s diverse biolog-
ical apparatus to maximize viral survival and transmis-
sibility. Some of these changes may not be as important 
as others. Van Dorp et al (2020) reported changes in the 
non-structural proteins Nsp6, Nsp11, Nsp13 as well as the 
trimeric spike [39]. However, if instead of the Nsp6, Nsp11 
and Nsp13, the non-structural proteins Nsp7, Nsp8, and 
Nsp12 in association with Nsp14 were involved, the an-
tigen’s capacity to replicate long viral RNA would have 
been compromised. Research on previous versions of 
the antigen indicated that the mutation of the nsp8 resi-
dues P183 and R190 that are involved in the interphase 
between nsp8 and nsp12 as well as K58 had deleterious 
effects for the virus [40].
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Another variant, the A222V that substitutes Alanine 
with Valine on the 222nd position, was linked to Italy and 
Spain and appeared to represent about 11.2% of the ge-
netic sequences collected from Covid-19 patients between 
June and October 2020. This mutant seemed to primarily 
affect immune recognition since it occured in the S protein 
segment that binds with the ACE2 receptor [41-42]. Overall 
D614G was manifested in around 86.5% of Covid-19 
infections, while other mutants, such as the A222V, were 
relatively less frequent. D614G was often present along 
with A222V, as well as other common mutations such as 
the S477N that exchanged Serine (S) with Asparagine (N) 
at the 477th position and L5F. Several other mutations have 
been identified such as the L18F reflecting a Leucine (L) 
exchange with Phenylalanine (F), the A262S involving a 
switch between Alanine (A) and Serine (S) and other far 
less frequent ones such as the T632N (Threonine to As-
paragine), V3G (Valine to Glycine), D574Y (Aspartate to 
Tyrosine), P272L (Proline to Leucine), D1163Y (Aspartate 
to Tyrosine), and others. The S protein contains around 
98,699 amino acid sequences, each consisting of around 
1273 amino acids. Around 3205 of these amino acid se-
quences that compose the Spike protein are unique, sug-
gesting that Covid-19 has evolved significantly, obtaining 
genetic diversity from previous versions of coronavirus. [43].
Recently, a highly contagious new mutant, the B117 
appeared in the UK in September 2020, currently ac-
counting for around two thirds of the UK cases, only after 
three months. Since then it has already spread to around 
24 USA states, and was recently identified in a few cases 
in Hong Kong. The B117 may have emerged as the virus 
multiplied within an infected immunocompromised pa-
tient, and it appears to be up to 70% more transmissible 
[44]. It combines around 23 mutants, primarily affecting 
the Spike protein, that include substitutions of amino acid 
Asparagine (N) with Tyrosine (Y) at the 501 position 
forming the mutant N501Y; amino acid Alanine (A) with 
Aspartate (D) at the 570 position, composing A570D; the 
D614G variant discussed above that involves replacement 
of Aspartate (D) with Glycine (G) at the 614 position; 
P681H entailing an interchange of Proline (P) with His-
tidine (H) at the 681 position; T716I reflecting a switch 
of Threonine (T) with Isoleucine (I) at the 716 position; 
the S982A featuring an exchange between Serine (S) 
and Alanine (A) at position 982; D1118H representing a 
commutation between Aspartate (D) with Histidine (H) 
at position 1118, etc [44]. Seventeen out of these 23 alter-
ations appear to have occurred simultaneously, expressing 
a successful viral transformation with the purpose to dis-
guise viral proteins compromising the antibodies’ efficacy 
against the infection. The mutation N501Y modifies the 
structure of the S protein camouflaging it from immune 
detection and threatening to eventually render ineffective 
all vaccines targeting the S protein. What is remarkable is 
that after undergoing around 300,000 mutations, Covid-19 
mutants have evolved into being more effective and con-
tagious rather than disintegrating into extinction, which 
is what would be expected if such accumulated mutations 
were random. As if there is some calculated intelligent 
programming within Covid-19 that renders mutations 
purposeful – something that has never been encountered 
previously in naturally occurring coronaviruses [45-46]. 
The 501.V2 variant which is at least as dangerously 
transmissible as the UK B117 has also been spreading 
globally. It is known to have three main substitutions of 
amino acid Lysine (K) to Asparagine (N) at the 417 posi-
tion (K417N); the variant E484K that involves Glutamate 
(E) being switched into Lysine (K) at position 484; and 
the mutant N501Y where Asparagine (N) is replaced by 
Tyrosine (Y) at the 501 position of the genetic sequence. 
The N501Y that is shared by both the B117 and the 501.
V2 and which enhances the affinity between the Spike 
protein and the ACE2 receptor appears to be compromised 
by the K417N and E484K variants, possibly rendering 
the African mutation less infectious and effective than the 
British one. These two transformations’ deleterious effects 
are based on the action of E484K and K417N resulting in 
disrupting the salt bridges developed by E484 and K417 
after these two variants have been transformed into 484K 
and 417 N that do not support salt bridges with BD23 
R108 / H11013 R52 and C105 E96/E99 respectively [47].
Additional highly contagious mutations like the 501Y.
V2 or, as otherwise termed, B1351, that shares a lot of the 
variants composing B117, and the P1 from Brazil have 
recently emerged. The 501Y.V2 includes 19 mutations, 
with nine of them located in the Spike protein including 
the N501Y (Asparagine being replaced by Tyrosine), the 
E484K (Glutamate being replaced by Lysine) and K417N 
(Lysine being exchanged by Asparagine). It also lodges 
mutations on the N-terminal domain, including L18F - 
replacing Leucine (L) with Phenylalanine (F) in the 18th 
position, D80A – transposing Aspartate (D) with Alanine 
(A) at the 80th position, and D215F that substitutes Aspar-
tate (D) by Phenylalanine (F) at the 215 position [48]. The 
P1 mutation displays 17 unique amino acid reversals, four 
nucleotide insertions and four deletions. P1, B117 and 
501Y.V2 all harbour the N501Y mutation that enhances the 
contact affinity between the Spike protein and the ACE2 
receptor, rendering the variant significantly more conta-
gious.A new variant that was first detected in India is now 
spreading around the world, diminishing the effectiveness 
of the Pfizer/BioNTech and AstraZeneca vaccines from 
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93% to 88% and from 66% to 60% respectively. 
5. Conclusions
Viral mutations have been long considered as random 
events, or mistakes during the RNA replication of a virus. 
Usually, what can go wrong will go wrong; therefore, re-
peated mutations lead to the extinction of a virus. Howev-
er, with Covid-19 the opposite has occurred. The aggregate 
result of over 300,000 Covid-19 changes has expanded the 
virus’ transmissibility and infectiousness. Covid-19 muta-
tions have not degraded the virus; they have empowered 
and facilitated its disguise to evade detection; which poses 
the question: Is this really a random mindless process or 
are we witnessing the unfolding of a learning expedition 
driving this virus to adjust and adapt, thus ensuring its 
maintenance and survival? 
Moreover, there is the hypothesis that Covid-19 in-
hibits the interferon type I production, compromising 
adaptive immunity from recognizing the virus; eventually 
leading to the deleterious consequences of the cytokine 
storm where the CD8+ killer cells injure the vital organs 
of the host. It may appear improbable that there is a pre-
meditated strategy to debilitate key systemic defences and 
prevail, yet, it may not be entirely impossible that evo-
lution has programmed Covid-19 with an adeptness, that 
distinguishes it from all previous coronavirus versions. 
If that is the case, the danger is exponentially increasing 
and our current observations are no more than a prelude to 
more elusive, inconspicuous, and far more sophisticated 
versions of this pandemic. 
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